retatrutide triple hormone receptor agonist Medscape | Retatrutide, Eli Lilly's first-in-class agonist, delivered meaningful weight loss at 80 weeks in all doses in the retatrutide trials dosage clinical trial

Understanding your genetic predispositions in peptide pathways may support informed decisions about treatment selection, monitoring timelines, and realistic expectationsenabling your provider to offer precision-informed care rather than applying assumptions based solely on BMI or clinical presentation

Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. American Journal of Lifestyle Medicine , 30 May 2025, Locatelli, Joo Carlos, et al

This term covers several treatments that use specific ingredients to target discoloration in unique ways

Lifestyle factors such as heavy smoking and drinking or a poor diet over a prolonged period can also lead to low B12 levels or deficiency